Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 5/20 | 0.49 |
| ▸ | PRKACA | P17612 | 4/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22971635 | 0.89 | ROCK1 (0.56) | ROCK1ROCK2PARP1ALDH1A1MPL | |
| SCHEMBL21241824 | 0.88 | PARP1 (0.50) | ROCK1ROCK2PARP1ALDH1A1KDM4E | |
| SCHEMBL21241972 | 0.88 | WNT3A (0.53) | ROCK1ROCK2PARP1PRKACAWNT3A | |
| SCHEMBL25502159 | 0.84 | ALDH1A1 (0.51) | ROCK1ROCK2PARP1ALDH1A1PRKACA | |
| SCHEMBL31173297 | 0.84 | WNT3A (0.57) | ROCK1ROCK2PARP1PRKACAWNT3A | |
| SCHEMBL22290890 | 0.84 | WNT3A (0.57) | ROCK1ROCK2PARP1PRKACAWNT3A | |
| SCHEMBL23704805 | 0.83 | MAPT (0.50) | ROCK1ROCK2PARP1ALDH1A1MPL | |
| SCHEMBL22306697 | 0.83 | ROCK1 (0.48) | ROCK1ROCK2PARP1ALDH1A1PRKACA | |
| SCHEMBL31173242 | 0.83 | PARP1 (0.47) | ROCK1ROCK2PARP1ALDH1A1PRKACA | |
| SCHEMBL22290647 | 0.83 | PARP1 (0.47) | ROCK1ROCK2PARP1ALDH1A1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ROCK1 4248/4885ROCK2 3927/4885PARP1 491/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ROCK1 4248/4885ROCK2 3927/4885PARP1 491/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ROCK1 1283/4885ROCK2 2299/4885PARP1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.